Infinimmune | News

News & Media

All

Press

Publications

Announcements

KBI Biopharma, Inc. Announces Collaboration with Infinimmune Inc. to Support Antibody Manufacturing

September 8, 2025

KBI Biopharma, Infinimmune Partner to Support Antibody Manufacturing

September 8, 2025

AI News: Alameda based Infinimmune launched its GLIMPSE-1 antibody engineering platform that is based on a protein language model focused on native human antibody sequences

Better Antibodies Engineered with GLIMPSE of Human Data

Infinimmune Launches GLIMPSE-1 AI Model Trained Exclusively on Human Antibody Sequences for Advanced Therapeutic Engineering

How Infinimmune is Transforming Therapeutic Antibody Engineering

Infinimmune’s AI Model GLIMPSE-1 Engineers Human-Sourced Antibodies

Insight on FDA’s Plan to Phase Out Animal Testing for mAbs and Other Drugs

FDA wants a shift away from animal testing

FDA wants to get rid of animal testing requirements for antibody drugs

Infinimmune Appoints Dr. Tim Sullivan as Chief Business Officer

September 3, 2024

Infinimmune Appoints Dr. Neela Patel to Board of Directors

Infinimmune, Grid Therapeutics Strike Antibody-Based Cancer Drug Discovery Partnership

January 5, 2024

Infinimmune Announces Partnership with Grid Therapeutics to Conduct Deep Sequencing of B Cells for Oncology Drug Discovery

December 19, 2023

Bio’s Next Tool Builders

Spotlight on Infinimmune

Founding Infinimmune and Developing Breakthrough Tools for Antibody Discovery

$12-Million Seed Funding to Design Drugs Using Human-Sourced Antibodies

December 6, 2022

Infinimmune Raises $12 Million in Seed Funding to Pioneer Novel Approach to Antibody Drug Discovery and Development

December 6, 2022

Infinimmune’s secret for building better antibody drugs: You

December 6, 2022